Introduction / objectives Management of anxiety and depression in rheumatoid arthritis (RA) patients is vital. Previous studies investigating this topic are conflicting, and this topic still has not been thoroughly investigated. This study aimed to clarify the association of disease activity with anxiety and depression after controlling for physical disability, pain, and treatment.Method We conducted a cross-sectional study of RA patients from the Kyoto University Rheumatoid Arthritis Management Alliance cohort. For assessments, we used the Disease Activity Score (DAS28), Health Assessment Questionnaire Disability Index (HAQ-DI), and Hospital Anxiety Depression Scale.Depression and anxiety were defined by a Hospital Anxiety Depression Scale score ≥8. We then performed multivariable logistic regression analyses. ResultsOf 517 participants, 17.9% had anxiety, and 28.2% had depression. The multivariable logistic regression analyses showed patients with DAS28-based non-remission had low association with anxiety (odds ratio [OR] [95% confidence interval {CI}], 0.93 [0.48-1.78]: p = 0.82) but slight association with depression (OR [95% CI], 1.45 [0.81-2.61]: p = 0.22). However, severity of the patient's global assessment (PtGA) on DAS28 was associated with anxiety (OR [95% CI], 1.15 [1.02-1.29]; p = 0.03) and depression (OR [95% CI], 1.21 [1.09-1.35]; p < 0.01). Additionally, HAQ-DI-based non-remission was associated with anxiety (OR [95% CI], 3.51 [1.85-6.64]; p < 0.01) and depression (OR [95% CI], 2.65 [1.56-4.50]; p < 0.01). Younger patients (OR [95% CI], 0.83 [0.68-1.01]; p = 0.07) and patients not treated with methotrexate (OR [95% CI], 0.67 [0 .40-1.13]; p = 0.13) tended to suffer from anxiety. Patients using steroids had a closer association with depression than those not using them (OR [95% CI], 1.66 [1.03-2.67]; p = 0.04).Conclusions Assessment of disease activity, PtGA, and HAQ-DI are important for assessing anxiety and depression in RA patients. Attention should be paid to improving PtGA and physical function.
Background Management of anxiety and depressive symptoms in rheumatoid arthritis (RA) patients is vital. Previous studies investigating this topic are conflicting, and this topic still has not been thoroughly investigated. This study aimed to clarify the association of disease activity with anxiety and depressive symptoms after controlling for physical disability, pain, and treatment.Methods We conducted a cross-sectional study of RA patients from the Kyoto University Rheumatoid Arthritis Management Alliance cohort. For assessments, we used the Disease Activity Score (DAS28), Health Assessment Questionnaire Disability Index (HAQ-DI), and Hospital Anxiety Depression Scale. Depression and anxiety were defined by a Hospital Anxiety Depression Scale score ≥8. We then performed multivariable logistic regression analyses.Results Of 517 participants, 17.9% had anxiety and 28.2% had depression. The multivariable logistic regression analyses showed that DAS28-based non-remission was not statistically associated with anxiety symptoms (odds ratio [OR] [95% confidence interval {CI}], 0.93 [0.48–1.78]: p = 0.82) and depressive symptoms (OR [95% CI], 1.45 [0.81–2.61]: p = 0.22). However, severity of the patient’s global assessment (PtGA) on DAS28 was associated with anxiety symptoms (OR [95% CI], 1.15 [1.02–1.29]; p = 0.03) and depressive symptoms (OR [95% CI], 1.21 [1.09–1.35]; p < 0.01). Additionally, HAQ-DI-based non-remission was associated with anxiety symptoms (OR [95% CI], 3.51 [1.85–6.64]; p < 0.01) and depressive symptoms (OR [95% CI], 2.65 [1.56–4.50]; p < 0.01). Patients using steroids had a closer association with depressive symptoms than those not using them (OR [95% CI], 1.66 [1.03–2.67]; p = 0.04).Conclusions As per the multivariable logistic regression analysis, there was no association between DAS28-based-non-remission and anxiety and depressive symptoms; however, the univariate analysis revealed such association. In the multivariate analysis, PtGA and non-remission on HAQ were associated with anxiety and depressive symptoms. Rather than focusing solely on controlling disease, activity and treatment should focus on improving or preserving physical function and patient's overall sense of well-being.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.